<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Several methods have been developed for the detection of <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>) in B cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Chromosomal translocations or the rearrangement of the immunoglobulin heavy chain (IgH) and T cell receptor genes are generally employed </plain></SENT>
<SENT sid="2" pm="."><plain>We report a novel PCR method to detect <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> using IgH genes </plain></SENT>
<SENT sid="3" pm="."><plain>IgH rearranged variable region (VDJ) were amplified from <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> specimens using consensus primers for variable and joining region genes </plain></SENT>
<SENT sid="4" pm="."><plain>Complementarity-determining regions (CDR) were identified and used to generate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific primers </plain></SENT>
<SENT sid="5" pm="."><plain>Two-round amplifications using primers derived from CDRs and joining or constant regions were performed for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> detection </plain></SENT>
<SENT sid="6" pm="."><plain>IgH nested-PCR approach was tested on a panel of 75 B cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> including <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic and <z:hpo ids='HP_0005550'>chronic lymphocytic leukemias</z:hpo>, non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and <z:hpo ids='HP_0006775'>multiple myelomas</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>A VDJ sequence was obtained in 62 out of 75 cases (83%) </plain></SENT>
<SENT sid="8" pm="."><plain>Sensitivity using DNA or cDNA templates was 10(-5) and (-6), respectively </plain></SENT>
<SENT sid="9" pm="."><plain>This method is specific and sensitive and provides a simple, non-radioactive approach for the evaluation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> in B cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
</text></document>